Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancer [0.03%]
Bavdegalutamide（ARV-110）与阿比特龙联合治疗转移性前列腺癌的Ib期试验
Martin Smoragiewicz,Alice Bernard-Tessier,Mark Linch et al.
Martin Smoragiewicz et al.
Purpose: Resistance to androgen receptor pathway inhibitors (ARPIs) necessitates development of regimens to improve outcomes in metastatic prostate cancer (mPC). This phase 1b clinical trial evaluated safety/tolerability ...
Next generation sequencing of circulating tumor DNA for precision medicine in patients with advanced biliary tract cancers [0.03%]
用于晚期胆道癌精确诊疗的循环肿瘤DNA测序研究
Laura Visa,Jordi Badia-Ramentol,Maria Concepción Fernández et al.
Laura Visa et al.
Purpose: NGS tissue testing is recommended in advanced biliary tract cancers (aBTC) due to increasing approval of targeted therapies. However, tissue NGS is frequently limited by poor access and insufficient tumor. We exp...
Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial [0.03%]
卢米埃尔一期试验：在晚期实体瘤患者中使用[177Lu]Lu-FAP-2286靶向纤维活化蛋白
Jonathan McConathy,Vadim S Koshkin,Yusuf Menda et al.
Jonathan McConathy et al.
Purpose: Fibroblast activation protein (FAP) is an attractive target for radiopharmaceutical therapy. Phase I of the LuMIERE study (ClinicalTrials.gov, NCT04939610) investigated the safety of [177Lu]Lu-FAP-2286 (177Lu-FAP...
Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade [0.03%]
局部晚期可切除头颈部皮肤鳞状细胞癌的非手术治疗与PD-1阻断疗法
Fergal G Kavanagh,Ryan S Instrum,Lillian A Boe et al.
Fergal G Kavanagh et al.
Purpose: Neoadjuvant PD-1 blockade has shown marked efficacy before surgery in patients with head and neck cutaneous squamous cell cancer (CSCC). However, the potential for PD-1 blockade as a definitive, non-operative the...
Intrathecal Allogeneic B7-H3-targeted CAR γδ T Cells for Leptomeningeal Metastasis from Solid Tumors: Safety, Efficacy, and Immunological Dynamics in a Phase 1 Trial [0.03%]
针对实体瘤脑膜转移的同种异体B7-H3靶向CARγδT细胞鞘内给药：I期临床试验的安全性、有效性和免疫学动力学研究
Peiwen Ma,Yongxin Zhou,Weiwei Ma et al.
Peiwen Ma et al.
Purpose: To evaluate intrathecal QH104, an allogeneic B7 homolog 3 (B7-H3)-targeted chimeric antigen receptor (CAR) γδ T-cell therapy, in patients with leptomeningeal metastasis (LM). ...
Mature Outcomes and Patterns of Failure in the Phase II FLARE-RT Trial of Biological Image-guided and Risk-Adaptive Chemoradiation for Unresectable NSCLC [0.03%]
FLARE-RT生物标志物引导和风险适应型放化疗II期临床试验的成熟结果及失败模式
Jing Zeng,Sunan Cui,Daniel S Hippe et al.
Jing Zeng et al.
Purpose: FLARE-RT tested personalized functional-lung-avoidance and response-adaptive radiotherapy intensification for unresectable non-small cell lung cancer (NSCLC) using FDG-PET/CT and SPECT/CT. We report mature outcom...
HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications [0.03%]
HRDetect在输卵管卵巢癌中的应用：分层和治疗意义
Kalyan Banda,Helen R Davies,Yogesh Kumar et al.
Kalyan Banda et al.
Purpose: To evaluate HRDetect, a mutational-signature-based algorithm, for prognostic utility in tubo-ovarian carcinoma (OC), and to determine if whole-genome sequencing (WGS) with rearrangement signature (RS) analysis ca...
Phase 1 evaluation of patients with newly diagnosed glioblastoma treated with radiation, nivolumab, and IDO1 enzyme inhibitor BMS-986205 [0.03%]
新诊断的胶质母细胞瘤患者放疗联合尼伏单抗和IDO1酶抑制剂BMS-986205Ⅰ期临床研究评估结果
Rimas V Lukas,Lijie Zhai,Kristen L Lauing et al.
Rimas V Lukas et al.
Background: We conducted a phase 1 trial to evaluate radiotherapy (RT) and nivolumab with the further addition of an IDO1 enzyme inhibitor (BMS-986205) in newly diagnosed patients with GBM IDHwt. ...
Clinical and molecular correlates of circulating tumor fraction in patients with metastatic pancreatic ductal adenocarcinoma [0.03%]
转移性胰腺导管腺癌患者循环肿瘤分数的临床和分子相关因素
James T Topham,Haley M Beckmann,Joanna M Karasinska et al.
James T Topham et al.
Purpose: Pre-existing and emerging molecular-targeted therapies have been identified for the treatment of pancreatic ductal adenocarcinoma (PDAC) and exemplify the need for incorporating tumor sequencing into routine clin...
Sensitivity to endocrine therapy index predicts benefit from weekly adjuvant paclitaxel for hormone receptor-positive breast cancer in the GEICAM/9906 trial [0.03%]
对内分泌治疗敏感性的指标能够预测GEICAM/9906试验中激素受体阳性乳腺癌患者从辅助周疗紫杉醇中的获益情况
Miguel Martín,Alvaro Rodriguez-Lescure,Cristina Reboredo et al.
Miguel Martín et al.
Purpose: To independently validate that low endocrine transcriptional activity measured by SETER/PR index in hormone receptor-positive breast cancer predicts benefit from dose-dense paclitaxel chemotherapy within a second...